Bio-Rad Anti-Brentuximab Vedotin and Anti-Secukinumab Antibodies.
HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab–interleukin 17A (IL-17A) drug-target complex. These sequence-defined antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for brentuximab vedotin, secukinumab, and their biosimilars.
Bio-Rad's anti-brentuximab vedotin and anti-secukinumab inhibitory antibodies are available in Fab (fragment antigen-binding) and fully human IgG1 formats with different affinities. The antibodies can be used to develop PK bridging ELISAs to measure free drug or as a surrogate positive control or reference standard in an ADA assay.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma by selectively targeting tumor cells expressing the CD30 antigen. The four new anti-brentuximab vedotin antibodies are specific to the brentuximab antibody alone, as well as when it is conjugated to the toxin monomethyl auristatin E.
Secukinumab binds to IL-17A, resulting in inhibition of the patient's inflammatory response in several diseases, including ankylosing spondylitis, psoriasis, and psoriatic arthritis. In addition to the four new inhibitory anti-secukinumab antibodies, Bio-Rad also offers the antibody specific to the anti-secukinumab–IL-17A complex. This antibody is suitable for use in a PK antigen capture assay, providing an alternative format to the PK bridging ELISA.
The recombinant antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply throughout the assay lifecycle.
"Bio-Rad's range of ready-made and well-characterized anti-idiotypic antibodies keeps growing, offering researchers enhanced flexibility for the development of custom bioanalytical drug assays against a wide range of marketed biologic drugs," said Jack Cooper, Bio-Rad Product Manager, Life Science Group. “Generated under stringent quality control for batch-to-batch consistency, these antibodies can produce translatable and reproducible results, ensuring assay reliability," he said.
The anti-brentuximab vedotin and anti-secukinumab antibodies are approved for in vitro research purposes, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and for patient monitoring.
For more information about Bio-Rad's anti-idiotypic antibodies, please visit bio-rad-antibodies.com/biotherapeutic-antibodies-bioanalysis-drug-monitoring.html.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. HUCAL and CYSDISPLAY are trademarks of MorphoSys AG in certain jurisdictions. ADCETRIS and COSENTYX are trademarks of their respective owners.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 7,900 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc.
Kate Smith, Director, Global Customer Engagement Marketing
510-741-5307
kate_smith@bio-rad.com
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com
To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.